Format

Send to:

Choose Destination
See comment in PubMed Commons below
Eur Rev Med Pharmacol Sci. 2006 Jul-Aug;10(4):173-8.

The pharmacologic basis of treatment with colchicine in children with familial Mediterranean fever.

Author information

  • 1Centre of Periodic Fevers, Department of Pediatric Sciences, Universit√† Cattolica del Sacro Cuore, Rome, Italy. drigante@rm.unicatt.it

Abstract

Familial Mediterranean fever (FMF) is the prototype of auto-inflammatory disorders and is ethnically restricted to people living in the Mediterranean basin and Middle-East. Pyrin, the protein product of the FMF gene, expressed in myeloid cells and fibroblasts, interacts with the cytoskeletal machinery and may modulate leukocyte effector functions. At present colchicine, an alkaloid with antimitotic activity interfering with microtubule formation, which has been used to alleviate acute gout, is the only available drug for patients with FMF to prevent both acute attacks and long-term complications such as amyloidosis. The anti-inflammatory effect of colchicine may be mediated not only through direct interaction with microtubules, but also through changes at the transcriptional level influencing cell cycle regulation and leukocyte migration. Gastrointestinal side effects may occur early and are the most frequent manifestations of colchicine toxicity in children, whilst multiple organ failure is very rarely reported as overdosage expression.

PMID:
16910346
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk